Prof. NURULLAH ZENGİN

Publication Network

Journal articles indexed in SCI, SSCI, and AHCI 180

1. Metastatic colorectal cancer in both sides of Aegean sea: practice patterns and outcome

YAZICI O., Ucar G., SÜTCÜOĞLU O., Turhal N. S., Yildiz B., Karamouzis M., et al.

Current Medical Research and Opinion , vol.38, pp.579-586, 2022 (SCI-Expanded) Sustainable Development

2. Conditioning Regimens for Relapsed/Refractory Lymphoma Patients Undergoing Autologous Stem Cell Transplantation: BEAM Versus High Dose ICE

Gunes A. K., Dagdas S., Ceran F., Ucar M. A., Falay M., Sunu C., et al.

Indian Journal of Hematology and Blood Transfusion , vol.37, no.1, pp.82-89, 2021 (SCI-Expanded)

3. Clinical outcomes of patients with pure small cell carcinoma of the urinary bladder

Erdem G. U., Dogan M., Aytekin A., Sahin S., Cinkir H. Y., Sakin A., et al.

Irish Journal of Medical Science , vol.189, no.2, pp.431-438, 2020 (SCI-Expanded)

4. A rare case: Branch retinal vein occlusion associated with the use of tamoxifen

DEMİRCİ N. S., Erdem G., Uçgun N., Bozkaya Y., Ozdemir N., Dogan M., et al.

Journal of Cancer Research and Therapeutics , vol.15, no.3, pp.722-724, 2019 (SCI-Expanded) Sustainable Development

5. The frequency and predictors of persistent amenorrhea in premenopausal women with colorectal cancer who received adjuvant chemotherapy

Sahin T., Dizdar O., Ozdemir N., ZENGİN N., Ates O., Oksuzoglu B., et al.

Anti-Cancer Drugs , vol.30, no.3, pp.289-294, 2019 (SCI-Expanded) Sustainable Development

6. Prognostic importance of the albumin to globulin ratio in metastatic gastric cancer patients

Bozkaya Y., Erdem G. U., DEMİRCİ N. S., Yazıcı O., Özdemir N. Y., Köstek O., et al.

Current Medical Research and Opinion , vol.35, no.2, pp.275-282, 2019 (SCI-Expanded) Sustainable Development

7. Is the Charlson comorbidity index a prognostic indicator for toxicity and mortality in elderly patients with locally advanced rectal cancer?

Köstek O., Bozkaya Y., Hacıoğlu M. B., Özdemir N. Y., Yılmaz E., Demircan N. C., et al.

Archives of Iranian Medicine , vol.22, no.5, pp.236-241, 2019 (SCI-Expanded) Sustainable Development

8. Mortality risk analysis of asymptomatic and symptomatic venous thromboembolism in patients with metastatic colorectal cancer

Bozkaya Y., Özdemir N., Erdem G., DEMİRCİ N. S., Yazici O., Hocazade C., et al.

Journal of Cancer Research and Therapeutics , vol.14, no.6, pp.1330-1335, 2018 (SCI-Expanded) Sustainable Development

9. Neutrophil–lymphocyte ratio, platelet–lymphocyte ratio, neutrophil–platelet score and prognostic nutritional index: do they have prognostic significance in metastatic pancreas cancer?

Dogan M., Algin E., Guven Z. T., Baykara M., Kos T. F., Bal O., et al.

Current Medical Research and Opinion , vol.34, no.5, pp.857-863, 2018 (SCI-Expanded) Sustainable Development

10. Non-Urothelial Bladder Cancer: Comparison of Clinicopathological and Prognostic Characteristics in Pure Adenocarcinoma and Non-Bilharzial Squamous Cell Carcinoma of the Bladder

Erdem G. U., Dogan M., Sakin A., Oruc Z., Yaman E., Yesil Cinkir H., et al.

Oncology Research and Treatment , vol.41, no.4, pp.220-225, 2018 (SCI-Expanded) Sustainable Development

11. A modified epirubicin and oxaliplatin plus capecitabine (EOX) regimen as a second- line therapy in patients with advanced gastric cancer

Bozkaya Y., Özdemir N. Y., Yazici O., DEMİRCİ N. S., Kurtipek A., Erdem G. U., et al.

Asian Pacific Journal of Cancer Prevention , vol.19, no.1, pp.283-290, 2018 (SCI-Expanded) Sustainable Development

12. 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) as a third-line chemotherapy treatment in metastatic gastric cancer, after failure of fluoropyrimidine, platinum, anthracycline, and taxane

Erdem G. U., Bozkaya Y., Ozdemir N. Y., DEMİRCİ N. S., Yazici O., ZENGİN N.

Bosnian Journal of Basic Medical Sciences , vol.18, no.2, pp.170-177, 2018 (SCI-Expanded)

13. Is serum survivin expression a predictive biomarker in locally advanced gastric cancer patients treated with neoadjuvant chemotherapy?

Bozkaya Y., Özdemir N. Y., Sezer S., Köstek O., DEMİRCİ N. S., Yazlcl O., et al.

Cancer Biomarkers , vol.22, no.1, pp.143-149, 2018 (SCI-Expanded) Sustainable Development

14. Advanced signet-ring cell carcinoma of the stomach: Clinicopathological characteristics of patients and efficacy of the modified docetaxel, cisplatin, and fluorouracil regimen

Bozkaya Y., Erdem G. U., Özdemir N. Y., Hocazade C., Yazici O., DEMİRCİ N. S., et al.

Journal of Cancer Research and Therapeutics , vol.14, no.10, 2018 (SCI-Expanded) Sustainable Development

15. Preoperative platelet-to-lymphocyte ratio is a predictor of prognosis in patients with ampullary carcinoma

DEMİRCİ N. S., Ozdemir N., Erdem G., Bozkaya Y., Yazici O., ZENGİN N.

Bratislava Medical Journal , vol.119, no.3, pp.180-186, 2018 (SCI-Expanded)

16. Comparison of gemcitabine monotherapy with gemcitabine and cisplatin combination in metastatic pancreatic cancer: A retrospective analysis

Ergun Y., Ozdemir N. Y., Guner E. K., Esin E., Sendur M. A., Koksoy E. B., et al.

Journal of B.U.ON. , vol.23, pp.116-121, 2018 (SCI-Expanded) Sustainable Development

17. Evaluation of Lymphoma Patients Receiving High-Dose Therapy and Autologous Stem Cell Transplantation: Experience of a Single Center

Bozkaya Y., Uncu D., Dağdaş S., Erdem G. U., Doğan M., Özet G., et al.

Indian Journal of Hematology and Blood Transfusion , vol.33, no.3, pp.361-369, 2017 (SCI-Expanded)

18. Effectiveness of low-dose oral etoposide treatment in patients with recurrent and platinum-resistant epithelial ovarian cancer

Bozkaya Y., Doğan M., Umut Erdem G., Tulunay G., Uncu H., Arık Z., et al.

Journal of Obstetrics and Gynaecology , vol.37, no.5, pp.649-654, 2017 (SCI-Expanded) Sustainable Development

19. Gastric adenocarcinoma with neuroendocrine differentiation: Clinicopathological features and efficacy of modified DCF chemotherapy

Bozkaya Y., Ozdemir N., Colak A., ZENGİN N.

Journal of B.U.ON. , vol.22, no.4, pp.919-925, 2017 (SCI-Expanded)

20. Is plasma caveolin-1 level a prognostic biomarker in metastatic pancreatic cancer?

DEMİRCİ N. S., Dogan M., Erdem G. U., Kacar S., Turhan T., Kilickap S., et al.

Saudi Journal of Gastroenterology , vol.23, no.3, pp.183-189, 2017 (SCI-Expanded) Sustainable Development

21. Comparison of pigmentary side effects of taxanes and anthracyclines: an onychoscopic evaluation

Yorulmaz A., Dogan M., Artuz F., ZENGİN N.

Cutaneous and Ocular Toxicology , vol.36, no.2, pp.135-139, 2017 (SCI-Expanded) Sustainable Development

22. Modified docetaxel, cisplatin and fluorouracil therapy as the first-line treatment for patients with recurrent/metastatic squamous cell carcinoma of the head and neck cancer: a retrospective study

Demirci N. S., Aksoy S., Özdemir N. Y., Erdem G. U., Ozcelik M., Tanrikulu E., et al.

Current Medical Research and Opinion , vol.33, no.3, pp.401-407, 2017 (SCI-Expanded) Sustainable Development

23. Comparative study of receptor discordance between primary and corresponding metastatic lesions in breast cancer

Erdem G. U., Altundag K., Ozdemir N. Y., Sahin S., Demirci N. S., Karatas F., et al.

Journal of B.U.ON. , vol.22, no.2, pp.365-376, 2017 (SCI-Expanded) Sustainable Development

24. Comparison of clinicopathological and prognostic characteristics in patients with mucinous carcinoma and signet ring cell carcinoma of the stomach

Bozkaya Y., Erdem G. U., Ozdemir N. Y., DEMİRCİ N. S., Hocazade C., Yazıcı O., et al.

Current Medical Research and Opinion , vol.33, no.1, pp.109-116, 2017 (SCI-Expanded) Sustainable Development

25. Reduced doses of docetaxel and cisplatinum plus 5 fluorouracil combination chemotherapy in metastatic esophagogastric adenocarcinoma: The impact on outcomes Metastatik özofagogastrik adenokarsinomlarda modifiye doz dosetaksel-sisplatin-5-fluorourasil kombinasyon tedavisi: Sonuçlara etkisi

Eren T., Ozdemir N., Yazici O., Imamoglu G. I., Yazilitas D., ARSLAN S. O., et al.

UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi , vol.27, no.3, pp.171-177, 2017 (SCI-Expanded)

26. A new angiogenesis prognostic index with VEGFA, PLGF, and angiopoietin 1 predicts survival in patients with advanced gastric cancer

Aktaş S. H., AKBULUT H., Yazici O., ZENGİN N., Akgün H. N., Üstüner Z., et al.

Turkish Journal of Medical Sciences , vol.47, no.2, pp.399-406, 2017 (SCI-Expanded)

27. Adding chemotherapy after neoadjuvant chemoradiation in locally advanced rectal cancer; Promising or not?

ŞENDUR M. A. N., Bilgin B., AKSOY S., Akinci B., Ozdemir N., Dede D. S., et al.

UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi , vol.27, no.3, pp.194-196, 2017 (SCI-Expanded)

28. Flare phenomenon in advanced colorectal cancer: Cessation of bevacizumab after predefined cycles of therapy may not affect outcome İleri evre kolorektal kanserli hastalarda alevlenme fenomeni: Önceden belirlenmiş sayida verilen bevasizumabin kesilmesi sağkalimi olumsuz etkilemeyebilir

Besen A. A., Kose F., Sumbul A. T., Ozdemir N., Ozyilkan O., ZENGİN N., et al.

UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi , vol.27, no.1, pp.53-59, 2017 (SCI-Expanded)

29. Prognostic effect of symptomatic and asymptomatic venous thromboembolism in patients with gastric cancer Mide kanserli hastalarda semptomatik ve asemptomatik venöz tromboembolizmin prognostik etkisi

Bozkaya Y., Ozdemir N., DEMİRCİ N. S., Erdem G. U., Yazici O., Arslan S., et al.

UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi , vol.27, no.2, pp.100-109, 2017 (SCI-Expanded)

30. The efficacy of modified docetaxel-cisplatin-5-fluorouracil regimen as first-line treatment in patients with alpha-fetoprotein producing gastric carcinoma

Bozkaya Y., Doğan M., Yazıcı O., Erdem G. U., DEMİRCİ N. S., ZENGİN N.

Bosnian Journal of Basic Medical Sciences , vol.17, no.2, pp.138-143, 2017 (SCI-Expanded)

31. The clinical and pathological features affecting the time of relapse in patients with early stage colorectal cancer

Yazilitas D., Özdemir N., Yazici O., Hocazade C., DEMİRCİ N. S., ZENGİN N.

Journal of Cancer Research and Therapeutics , vol.12, no.4, pp.1257-1260, 2016 (SCI-Expanded) Sustainable Development

32. Prognostic role of pretreatment platelet/lymphocyte ratio in patients with non-small cell lung cancer

Kos M., Hocazade C., Kos F. T., Uncu D., Karakas E., Dogan M., et al.

Wiener Klinische Wochenschrift , vol.128, no.17-18, pp.635-640, 2016 (SCI-Expanded) Sustainable Development

33. Accessory spleen hypertrophy mimicking colon cancer metastasis

Ates I., Yazici O., Yazilitas D., Ozdemir N., ZENGİN N.

Experimental Oncology , vol.38, no.3, pp.202-203, 2016 (SCI-Expanded) Sustainable Development

34. Impact of laboratory test use strategies in a Turkish hospital

Yilmaz F. M., Kahveci R., Aksoy A., Kucuk E. Ö., Akin T., Mathew J. L., et al.

PLoS ONE , vol.11, no.4, 2016 (SCI-Expanded)

35. Evaluation of prognostic factors in localized high-grade undifferentiated pleomorphic sarcoma: report of a multi-institutional experience of Anatolian Society of Medical Oncology

Ozcelik M., Seker M., Eraslan E., Koca S., Yazilitas D., Ercelep O., et al.

Tumor Biology , vol.37, no.4, pp.5231-5237, 2016 (SCI-Expanded)

36. Oxaliplatin-induced acute thrombocytopenia

Erdem G., Dogan M., DEMİRCİ N. S., ZENGİN N.

Journal of Cancer Research and Therapeutics , vol.12, no.2, pp.509-514, 2016 (SCI-Expanded) Sustainable Development

37. Small cell carcinoma of the urinary bladder: Changing trends in the current literature

Erdem G. U., Özdemir N. Y., DEMİRCİ N. S., Şahin S., Bozkaya Y., ZENGİN N.

Current Medical Research and Opinion , vol.32, no.6, pp.1013-1021, 2016 (SCI-Expanded) Sustainable Development

38. The effect of the gastrectomy on survival in patients with metastatic gastric cancer: A study of ASMO

Yazici O., Özdemir N., Duran A. O., Menekşe S., Nahit Şendur M. A., Karaca H., et al.

Future Oncology , vol.12, no.3, pp.343-354, 2016 (SCI-Expanded) Sustainable Development

39. First hematopoietic cell transplantation in Uzbekistan: Progress through education and cooperation

Karimov K., Tekgündüz E., Saidov A., Kayikçi Ö., Boboev K., Koçubaba Ş., et al.

Transfusion and Apheresis Science , vol.54, no.1, pp.60-62, 2016 (SCI-Expanded)

40. Targeted therapies are new hope for patients with spinal radionecrosis

Hocazade C., Ozdemir N. Y., Yazici O., Oztekin Z. N., ZENGİN N.

UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi , vol.26, no.2, pp.126-128, 2016 (SCI-Expanded)

41. Effect of body mass index on the efficacy of adjuvant tamoxifen in premenopausal patients with hormone receptor positive breast cancer

ŞENDUR M. A. N., AKSOY S., Ozdemir N. Y., ZENGİN N., Yazici O., Sever A. R., et al.

Journal of B.U.ON. , vol.21, no.1, pp.27-34, 2016 (SCI-Expanded) Sustainable Development

42. A retrospective comparison of early stage primary extranodal with nodal non-Hodgkin lymphoma patients: A single center experience

Yazilitas D., Özdemir N., Hocazade C., Bozkaya Y., Yazici O., ŞENDUR M. A. N., et al.

Journal of B.U.ON. , vol.20, no.6, pp.1526-1533, 2015 (SCI-Expanded)

43. Squamous cell and neuroendocrine carcinoma of esophagus: Collision versus composite tumor: A case report and review of literature

Yazici O., AKSOY S., Ozhamam E., ZENGİN N.

Indian Journal of Cancer , vol.52, no.4, pp.603-604, 2015 (SCI-Expanded)

44. A rare case: Hallucination associated with pazopanib

DEMİRCİ N. S., Erdem G. U., Dogan M., Ozdemir N. Y., ZENGİN N.

Journal of Cancer Research and Therapeutics , vol.11, no.4, pp.961-962, 2015 (SCI-Expanded) Sustainable Development

45. Rectal cancer with metastasis to the face

Yazilitas D., Dogan M., Ileri A. B., Ozdemir N., DEMİRCİ N. S., ZENGİN N.

UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi , vol.25, no.2, pp.145-147, 2015 (SCI-Expanded)

46. The relationship between platelet-lymphocyte ratio, neutrophil-lymphocyte ratio, and survival in metastatic gastric cancer on firstline modified docetaxel and cisplatinum plus 5 Fluorourasil Regimen: A single institute experience

Dogan M., Eren T., Ozdemir N., Cigirgan C. L., ZENGİN N.

Saudi Journal of Gastroenterology , vol.21, no.5, pp.320-324, 2015 (SCI-Expanded) Sustainable Development

47. Unusual metastases of lung cancer: bulbus oculi and maxillary sinus

Ates I., Yazici O., Ates H., Ozdemir N., ZENGİN N.

Experimental oncology , vol.37, no.3, pp.231-232, 2015 (SCI-Expanded) Sustainable Development

48. Concordance of positron emission tomography and computed tomography in patients with locally advanced gastric and esophageal cancer

Hocazade C., Özdemir N., Yazici O., Bozkaya Y., Yazılıtaş D., Toptaş Ş., et al.

Annals of Nuclear Medicine , vol.29, no.7, pp.621-626, 2015 (SCI-Expanded) Sustainable Development

49. The effect of obesity on recurrence pattern in early breast cancer patients

Yazici O., AKSOY S., Sendur M. A. N., Babacan T., Ozdemir N., Ozisik Y., et al.

Journal of B.U.ON. , vol.20, no.4, pp.954-962, 2015 (SCI-Expanded) Sustainable Development

50. Actual benefit of chemo-hormonal therapy in non-castrate metastatic prostate cancer

ŞENDUR M. A. N., AKINCI M. B., Ozdemir N. Y., AKSOY S., Dede D. S., Ulas A., et al.

Future Oncology , vol.11, no.8, pp.1141-1143, 2015 (SCI-Expanded) Sustainable Development

51. A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma

Erdem G. U., Sendur M. A. N., Ozdemir N. Y., Yazici O., ZENGİN N.

Current Medical Research and Opinion , vol.31, no.4, pp.743-756, 2015 (SCI-Expanded) Sustainable Development

52. Comparison of the long term cardiac effects associated with 9 and 52 weeks of trastuzumab in HER2-positive early breast cancer

ŞENDUR M. A. N., AKSOY S., YORGUN H., Ozdemir N., Yilmaz F. M., Yazici O., et al.

Current Medical Research and Opinion , vol.31, no.3, pp.547-556, 2015 (SCI-Expanded) Sustainable Development

53. Role of obesity on the efficacy of exemestane plus ovarian suppression in hormone receptor-positive premenopausal breast cancer

Nahit Şendur M. A., AKSOY S., Bülent Akinci M., Ozdemir N., ŞENER DEDE D., Altundag K., et al.

Future Oncology , vol.11, no.6, pp.905-907, 2015 (SCI-Expanded) Sustainable Development

54. Association between blood urea nitrogen/albumin ratio and prognosis in non-small cell lung cancer

Kos M., Hocazade C., Kos F. T., Uncu D., Karakas E., Dogan M., et al.

Acta Medica Mediterranea , vol.31, no.2, pp.219-223, 2015 (SCI-Expanded) Sustainable Development

55. Efficacy of dose dense doxorubicin and cyclophosphamide followed by paclitaxel versus conventional dose doxorubicin, cyclophosphamide followed by paclitaxel or docetaxel in patients with node-positive breast cancer: A retrospective study of the Anatolian Society of Medical Oncology

Yazilitas D., ŞENDUR M. A. N., Karaca H., Ozdemir N., AKSOY S., Berk V., et al.

Asian Pacific Journal of Cancer Prevention , vol.16, no.4, pp.1471-1477, 2015 (SCI-Expanded)

56. Trastuzumab-based retreatment after lapatinib in heavily pretreated HER2 positive metastatic breast cancer: An anatolian society of medical oncology study

Uncu D., Bayoglu I. V., Arslan U. Y., Kucukoner M., Artac M., Koca D., et al.

Asian Pacific Journal of Cancer Prevention , vol.16, no.9, pp.4127-4131, 2015 (SCI-Expanded)

57. Assessment of prognostic value of "neutrophil to lymphocyte ratio" and "prognostic nutritional index" as a sytemic inflammatory marker in non-small cell lung cancer

Kos F. T., Hocazade C., Kos M., Uncu D., Karakas E., Dogan M., et al.

Asian Pacific Journal of Cancer Prevention , vol.16, no.9, pp.3997-4002, 2015 (SCI-Expanded)

58. Duodenal adenocarcinoma: A rare cause of chyloperitoneum (chylous ascites)

Civelek B., AKSOY S., Kos T., Arik Z., Akinci M., Uncu D., et al.

Indian Journal of Cancer , vol.52, no.1, pp.109, 2015 (SCI-Expanded)

59. The efficacy of adjuvant trastuzumab in HER-2 positive breast cancer with axillary lymph node metastases according to the treatment duration

ŞENDUR M. A. N., AKSOY S., Ozdemir N. Y., Yazici O., ZENGİN N., Altundag K.

Current Medical Research and Opinion , vol.30, no.12, pp.2535-2542, 2014 (SCI-Expanded) Sustainable Development

60. Lanreotide in metastatic enteropancreatic neuroendocrine tumors

Ozdemir N., Yazici O., ZENGİN N.

New England Journal of Medicine , vol.371, no.16, pp.1555-1557, 2014 (SCI-Expanded)

61. The clinicopathological characteristics with long-term outcomes in malignant mesothelioma

Dogan M., UTKAN G., Hocazade C., Uncu D., Toptas S., Ozdemir N., et al.

Medical Oncology , vol.31, no.10, pp.1-6, 2014 (SCI-Expanded)

62. Adjuvant chemotherapy outcomes in patients over 65 years with early stage colorectal carcinoma

Civelek B., AKSOY S., Sendur M. A. N., Yazici O., Kanmaz H., Kos F. T., et al.

Journal of B.U.ON. , vol.19, no.4, pp.906-912, 2014 (SCI-Expanded) Sustainable Development

63. Metastatic parenchymal renal squamous cell carcinoma with hypercalcemia

Açıkgöz Y., ŞENDUR M. A. N., AKSOY S., Özdemir N. Y., ZENGİN N.

Medical Oncology , vol.31, no.9, pp.1-2, 2014 (SCI-Expanded)

64. Comparison the efficacy of second-line modified EOX (epirubicin, oxaliplatin, and capecitabine) and irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) regimens in metastatic gastric cancer patients that progressed on first-line modified docetaxel and cisplatin plus fluorouracil (DCF) regimen

Sendur M. A. N., Ozdemir N., Özatlı T., Yazıcı O., Aksoy S., Ekinci A. Ş., et al.

Medical Oncology , vol.31, no.9, pp.1-8, 2014 (SCI-Expanded) Sustainable Development

65. Impact of acetylsalicylic acid on the clinicopathological characteristics and prognosis of patients with invasive breast cancer

Sendur M. A., AKSOY S., Ozdemir N. Y., ZENGİN N., Altundag K.

Breast Care , vol.9, no.4, pp.261-266, 2014 (SCI-Expanded)

66. Longest progression-free survival with lapatinib and capecitabine combination followed by trastuzumab in HER2-positive brain metastatic breast cancer

Şendur M. A. N., Uncu D., ZENGİN N.

Medical Oncology , vol.31, no.4, 2014 (SCI-Expanded) Sustainable Development

67. Statin use may improve clinicopathological characteristics and recurrence risk of invasive breast cancer

Şendur M. A. N., AKSOY S., Yazici O., Ozdemir N. Y., ZENGİN N., Altundag K.

Medical Oncology , vol.31, no.2, 2014 (SCI-Expanded) Sustainable Development

68. Clinicopathologic features and prognosis of osteosarcoma in Turkish adults

Seker M. M., Seker A., AKSOY S., Ozdemir N., Uncu D., ZENGİN N.

Asian Pacific Journal of Cancer Prevention , vol.15, no.8, pp.3537-3540, 2014 (SCI-Expanded)

69. Everolimus: A new hope for patients with breast cancer

Sendur M. A., ZENGİN N., AKSOY S., Altundag K.

Current Medical Research and Opinion , vol.30, no.1, pp.75-87, 2014 (SCI-Expanded) Sustainable Development

70. Flurbiprofen-induced unilateral eyelid angioedema

ŞENDUR M. A. N., AKSOY S., Özdemir N. Y., Yaman Ş., ZENGİN N.

Cutis , vol.94, no.4, 2014 (SCI-Expanded)

71. Current approaches for prophylactic cranial irradiation in extrapulmonary small cell carcinoma

Yazici O., Ozdemir N. Y., Sendur M. A., AKSOY S., ZENGİN N.

Current Medical Research and Opinion , vol.30, no.7, pp.1327-1336, 2014 (SCI-Expanded) Sustainable Development

72. Efficacy and safety of first line Vincristine with doxorubicin, bleomycin and dacarbazine (ABOD) for Hodgkin's lymphoma: A single Institute experience

Ozdemir N., Dogan M., ŞENDUR M. A. N., Yazici O., Abali H., Yazilitas D., et al.

Asian Pacific Journal of Cancer Prevention , vol.15, no.20, pp.8715-8718, 2014 (SCI-Expanded)

73. Evaluation of the effect of comorbidity on survival in pancreatic cancer by using "charlson Comorbidity Index" and "cumulative Illness Rating Scale"

Kos F. T., Yazici O., Civelek B., Seker M., ARIK Z., AKSOY S., et al.

Wiener Klinische Wochenschrift , vol.126, no.1-2, pp.36-41, 2014 (SCI-Expanded) Sustainable Development

74. Effect of port-care frequency on venous port catheter-related complications in cancer patients

Odabas H., Ozdemir N. Y., Ziraman I., AKSOY S., Abali H., Oksuzoglu B., et al.

International Journal of Clinical Oncology , vol.19, no.4, pp.761-766, 2014 (SCI-Expanded) Sustainable Development

75. Prognostic factors in operated stage IIIC, pathological N3a breast cancer patients

Turker I., Arslan U. Y., Yazici O., Uyeturk U., Oksuzoglu B., Budakoglu B., et al.

Breast Care , vol.9, no.6, pp.421-427, 2014 (SCI-Expanded)

76. Can targeted programmed death-1 antibody be a new treatment approach in breast cancer

Sendur M. A. N., AKSOY S., Demirci S., Ozdemir N. Y., ZENGİN N., Altundag K.

Journal of B.U.ON. , vol.19, no.2, pp.584, 2014 (SCI-Expanded) Sustainable Development

77. Recurrence risk and prognostic parameters in stage I rectal cancers

Cihan S., Kucukoner M., Ozdemir N., Dane F., Sendur M. A. N., Yazilitas D., et al.

Asian Pacific Journal of Cancer Prevention , vol.15, no.13, pp.5337-5341, 2014 (SCI-Expanded)

78. Longest survival of lung metastatic ameloblastoma with a rare cause of malignant hypercalcemia

Açikgöz Y., Sendur M. A. N., Özdemir N. Y., AKSOY S., Uncu D., ZENGİN N.

Journal of Cranio-Maxillofacial Surgery , vol.42, no.4, pp.277-278, 2014 (SCI-Expanded)

79. Lung cancer screening: A comprehensive review of the literature with detailed data Akciğer Kanseri Taraması: Literatürün Güncel Veriler Eşliğinde Detaylı İncelenmesi

Acikgoz Y., ŞENDUR M. A. N., Ozdemir N. Y., AKSOY S., ZENGİN N.

UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi , vol.24, no.4, pp.270-278, 2014 (SCI-Expanded)

80. Serum 25-hydroxy vitamin D status is not related to steopenia/osteoporosis risk in colorectal cancer survivors

AKINCI M. B., Sendur M. A. N., AKSOY S., Yazici O., Ozdemir N. Y., Kos T., et al.

Asian Pacific Journal of Cancer Prevention , vol.15, no.8, pp.3377-3381, 2014 (SCI-Expanded) Sustainable Development

81. Treatment and outcomes of ewing sarcoma in Turkish Adults: A single centre experience

Seker M. M., Kos T., Ozdemir N., Seker A., AKSOY S., Uncu D., et al.

Asian Pacific Journal of Cancer Prevention , vol.15, no.1, pp.327-330, 2014 (SCI-Expanded)

82. Is programmed cell death ligand-1 expression required for optimal response to anti-PD-1 antibody in cancer

Sendur M. A. N., AKSOY S., Yildirim Ozdemir N., AKINCI M. B., ZENGİN N., Altundag K.

Journal of B.U.ON. , vol.19, no.2, pp.577-578, 2014 (SCI-Expanded) Sustainable Development

83. Acupuncture as a complementary treatment for cancer patients receiving chemotherapy

Tas D., Uncu D., Sendur M. A., Koca N., ZENGİN N.

Asian Pacific Journal of Cancer Prevention , vol.15, no.7, pp.3139-3144, 2014 (SCI-Expanded)

84. Evaluation of erectile dysfunction risk factors in young male survivors of colorectal cancer

Sendur M. A. N., AKSOY S., Ozdemir N. Y., Yaman S., Yazici O., AKINCI M. B., et al.

Journal of B.U.ON. , vol.19, no.1, pp.115-123, 2014 (SCI-Expanded) Sustainable Development

85. Necrotizing fasciitis secondary to bevacizumab treatment for metastatic rectal adenocarcinoma

Şendur M. A., AKSOY S., Özdemir N. Y., ZENGİN N.

Indian Journal of Pharmacology , vol.46, no.1, pp.125-126, 2014 (SCI-Expanded) Sustainable Development

86. Analysis of resected gastric cancer in Turkish population.

Demir G., Unsal D., ZENGİN N., Er O., Dane F., Yalçin S., et al.

Hepato-gastroenterology , vol.61, no.129, pp.259-266, 2014 (SCI-Expanded) Sustainable Development

87. Docetaxel, cisplatin, and fluorouracil combination in neoadjuvant setting in the treatment of locally advanced gastric adenocarcinoma: Phase II NEOTAX study

Ozdemir N., Abali H., Vural M., YALÇIN Ş., Oksuzoglu B., Civelek B., et al.

Cancer Chemotherapy and Pharmacology , vol.74, no.6, pp.1139-1147, 2014 (SCI-Expanded) Sustainable Development

88. A comparative study of low-profile and regular type totally implantable venous access devices in patients with malignant tumors: Retrospective analysis of 4501 implantations Malign tümörlü olgularda düşük profilli ve standard tip TİVEC kullani{dotless}mi{dotless}ni{dotless}n karşi{dotless}laşti{dotless}rmali{dotless} çali{dotless}şmasi{dotless}: 4501 olgunun retrospektif analizi

Akmangit I., Dede D., Daglioglu E., Sayin B., Peker A., Uncu D., et al.

UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi , vol.24, no.2, pp.97-105, 2014 (SCI-Expanded)

89. Predictors of outcome in patients with advanced nonseminomatous germ cell testicular tumors

Yetisyigit T., Babacan N., ÜRÜN Y., Seber E. S., Cihan S., Arpaci E., et al.

Asian Pacific Journal of Cancer Prevention , vol.15, no.2, pp.831-835, 2014 (SCI-Expanded)

90. Bevacizumab + capecitabine as maintenance therapy after initial bevacizumab + XELOX treatment in previously untreated patients with metastatic colorectal cancer: Phase iii 'stop and go' study results - A turkish oncology group trial

YALÇIN Ş., Uslu R., Dane F., Yilmaz U., ZENGİN N., Buyukunal E., et al.

Oncology (Switzerland) , vol.85, no.6, pp.328-335, 2013 (SCI-Expanded)

91. A rare coincidence: Facioscapulohumeral muscular dystrophy and breast cancer

Yazici O., AKSOY S., Ozdemir N., Sendur M., Dogan M., ZENGİN N.

Experimental Oncology , vol.35, no.4, pp.311-312, 2013 (SCI-Expanded) Sustainable Development

92. Clinicopathologic features of gastric cancer in young patients

Seker M., AKSOY S., Ozdemir N., Uncu D., ZENGİN N.

Saudi Journal of Gastroenterology , vol.19, no.6, pp.258-261, 2013 (SCI-Expanded) Sustainable Development

93. Capecitabine/cisplatin doublet in anthracycline and taxane pretreated and HER-2 negative metastatic breast carcinoma patients

Ozdemir N., AKSOY S., Sendur M., Akinci M., Yazici O., Budakoglu B., et al.

Journal of B.U.ON. , vol.18, no.4, pp.831-837, 2013 (SCI-Expanded)

94. Comparative efficacy study of 5-year letrozole or anastrozole in postmenopausal hormone receptor-positive early breast cancer

Sendur M., AKSOY S., ZENGİN N., Altundag K.

Journal of B.U.ON. , vol.18, no.4, pp.838-844, 2013 (SCI-Expanded) Sustainable Development

95. Arrhythmias during and after zoledronic acid infusion patients with bone metastasis

Yazici O., Aksoy S., Ucar O., Ozdemir N., Demir M., Sendur M. A. N., et al.

Medical Oncology , vol.30, no.3, 2013 (SCI-Expanded) Sustainable Development

96. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients

Arslan U., Turker I., AKSOY S., Oksuzoglu B., Helvaci K., Yildirim Ozdemir N., et al.

Journal of B.U.ON. , vol.18, no.3, pp.585-593, 2013 (SCI-Expanded) Sustainable Development

97. Variations in tumor marker levels in metastatic breast cancer patients according to tumor subtypes

Kos T., AKSOY S., Sendur M., ARIK Z., Civelek B., Kandemir N., et al.

Journal of B.U.ON. , vol.18, no.3, pp.608-613, 2013 (SCI-Expanded) Sustainable Development

98. Does trastuzumab-emtansine have better cardiac safety profile in contrast to trastuzumab?

Sendur M. A. N., AKSOY S., Ozdemir Y., ZENGİN N., Altundag K.

Journal of B.U.ON. , vol.18, no.3, pp.801, 2013 (SCI-Expanded)

99. Evaluation of the renal function using cystatin C level in the patients receiving cisplatin-based chemotherapy

Kos F., Sendur M., AKSOY S., Sezer S., Civelek B., Yazici O., et al.

Renal Failure , vol.35, no.5, pp.705-710, 2013 (SCI-Expanded)

100. Breast cancer in octogenarian women: Clinical characteristics and outcome

Kuzan T., Koca E., Dizdar O., Arslan C., Eren T., Yalcin S., et al.

Journal of B.U.ON. , vol.18, no.2, pp.328-334, 2013 (SCI-Expanded) Sustainable Development

101. Tyrosine kinase inhibitors may change the metastatic pattern

Sendur M. A. N., AKSOY S., Ozdemir N., ZENGİN N.

Journal of B.U.ON. , vol.18, no.2, pp.544, 2013 (SCI-Expanded)

102. Results of adjuvant FOLFOX regimens in stage III colorectal cancer patients: Retrospective analysis of 667 patients anatolian society of medical oncology

Uncu D., Aksoy S., Çetin B., Yetişyiǧit T., Özdemir N., Berk V., et al.

Oncology (Switzerland) , vol.84, no.4, pp.240-245, 2013 (SCI-Expanded) Sustainable Development

103. Evaluation of renal function using the level of neutrophil gelatinase-associated lipocalin is not predictive of nephrotoxicity associated with cisplatin-based chemotherapy

Tugba Kos F., Sendur M. A. N., AKSOY S., Celik H. T., Sezer S., Civelek B., et al.

Asian Pacific Journal of Cancer Prevention , vol.14, no.2, pp.1111-1114, 2013 (SCI-Expanded)

104. Detection of circulating tumor cells in breast cancer patients: Prognostic predictive role

Turker I., Uyeturk U., Sonmez O. U., Oksuzoglu B., Helvaci K., Arslan U. Y., et al.

Asian Pacific Journal of Cancer Prevention , vol.14, no.3, pp.1601-1607, 2013 (SCI-Expanded)

105. Importance of serum SELDI-TOF-MS analysis in the diagnosis of early lung cancer

Şimşek C., Sónmez Ó., YURDAKUL A. S., Ózmen F., ZENGİN N., Keyf A. I., et al.

Asian Pacific Journal of Cancer Prevention , vol.14, no.3, pp.2037-2042, 2013 (SCI-Expanded)

106. Does zoledronic acid have additive effect on suppression of plasma estrogen levels?

Şendur M. A. N., AKSOY S., Özdemir N. Y., Akinci M. B., ZENGİN N., Altundaǧ K.

Asian Pacific Journal of Cancer Prevention , vol.14, no.1, pp.607-608, 2013 (SCI-Expanded)

107. Is exon mutation analysis needed for adjuvant treatment of gastrointestinal stromal tumor?

Şendur M. A. N., Özdemir N. Y., Akinci M. B., Uncu D., ZENGİN N., AKSOY S.

World Journal of Gastroenterology , vol.19, no.1, pp.144-146, 2013 (SCI-Expanded)

108. Administration of contrast media just before cisplatin-based chemotherapy increases cisplatin-induced nephrotoxicity

Sendur M. A. N., AKSOY S., Yaman S., Arik Z., Tugba Kos F., AKINCI M. B., et al.

Journal of B.U.ON. , vol.18, no.1, pp.274-280, 2013 (SCI-Expanded) Sustainable Development

109. Demographic features and factors affecting overall survival in patients with hepatocellular carcinoma: A retrospective analysis in Turkey

Uyeturk U., Kos F. T., Helvaci K., Sonmez O. U., Turker I., Aktas G., et al.

Acta Medica Mediterranea , vol.29, no.4, pp.617-623, 2013 (SCI-Expanded) Sustainable Development

110. Is HER2 overexpression sufficient for optimal response to Pertuzumab?

Şendur M. A. N., AKSOY S., Yaman Ş., Özdemir N. Y., ZENGİN N.

Medical Oncology , vol.29, no.4, pp.2565-2566, 2012 (SCI-Expanded)

111. Demographic and clinico-pathological characteristics of breast cancer patients with history of oral alendronate use

Şendur M. A. N., AKSOY S., Yaman Ş., ArIk Z., Özdemir N. Y., ZENGİN N., et al.

Medical Oncology , vol.29, no.4, pp.2601-2605, 2012 (SCI-Expanded) Sustainable Development

112. Efficacy of adjuvant aromatase inhibitor in hormone receptor-positive postmenopausal breast cancer patients according to the body mass index

Şendur M., AKSOY S., ZENGİN N., Altundag K.

British Journal of Cancer , vol.107, no.11, pp.1815-1819, 2012 (SCI-Expanded)

113. New treatment trends in small cell carcinoma of the urinary bladder

Sendur M. A. N., AKSOY S., Yazici O., Akinci M., Ozdemir N., ZENGİN N.

Journal of B.U.ON. , vol.17, no.4, pp.799-800, 2012 (SCI-Expanded)

114. Multiple primary malignant neoplasms: Multi-center results from Turkey

Babacan N., Aksoy S., Cetin B., Ozdemir N., Benekli M., Uyeturk U., et al.

Journal of B.U.ON. , vol.17, no.4, pp.770-775, 2012 (SCI-Expanded) Sustainable Development

115. Dermatomyositis complicated with a soft tissue sarcoma

Şendur M. A. N., AKSOY S., Yaman Ş., Arik Z., Kilinç L., ZENGİN N.

Rheumatology International , vol.32, no.10, pp.3329-3330, 2012 (SCI-Expanded)

116. Frequency of HCV infection in renal cell carcinoma patients

Budakoǧlu B., Aksoy S., Arslan Ç., Üyetürk Ü., Babacan N. A., Özcan M. F., et al.

Medical Oncology , vol.29, no.3, pp.1892-1895, 2012 (SCI-Expanded) Sustainable Development

117. Isolated testicular metastasis of gastric cancer

Civelek B., Aksoy S., Kös T., Şeker M. M., Arik Z., Şendur M. A. N., et al.

Journal of Gastrointestinal Cancer , vol.43, no.SUPPL. 1, 2012 (SCI-Expanded)

118. Retrospective analysis of seventy-one patients with neuroendocrine tumor and review of the literature

Dogan M., Yalcin B., Ozdemir N. Y., Arslan U. Y., Dogan L., UTKAN G., et al.

Medical Oncology , vol.29, no.3, pp.2021-2026, 2012 (SCI-Expanded) Sustainable Development

119. Can bevacizumab be a new treatment approach in metastatic melanoma?

Nahit Sendur M. A., Ozdemir N., AKSOY S., Akinci M., ZENGİN N.

Journal of B.U.ON. , vol.17, no.3, pp.601-602, 2012 (SCI-Expanded)

120. Plasma VEGF levels may not accurately reflect the truth all the time

Şendur M. A. N., AKSOY S., Yaman Ş., Arik Z., Özdemir N. Y., ZENGİN N.

Medical Oncology , vol.29, no.2, pp.1403-1404, 2012 (SCI-Expanded)

121. Successful treatment of chronic hiccup with baclofen in cancer patients

Şeker M. M., AKSOY S., Özdemir N. Y., Uncu D., Civelek B., Akinci M. B., et al.

Medical Oncology , vol.29, no.2, pp.1369-1370, 2012 (SCI-Expanded) Sustainable Development

122. Pertuzumab plus trastuzumab in metastatic breast cancer [1]

Şendur M. A. N., AKSOY S., ZENGİN N.

New England Journal of Medicine , vol.366, no.14, pp.1348-1350, 2012 (SCI-Expanded) Sustainable Development

123. Evaluation of relationship between serum protein profiles and lung cancer by SELDI-TOF-MS (surface enhanced laser desabsorbtion ionization time of flight mass spectrometry) method Akciǧer kanseri ile serum protein profılleri arasındaki i̇lişkinin SELDI-TOF-MS (Surface enhanced laser desabsorbation ionization time of flight mass spectrometry) yöntemi ile deǧerlendirilmesi

YURDAKUL A. S., Sönmez Ö., Şimşek C., ZENGİN N., Keyf A. I., ÖZTÜRK C., et al.

Turkiye Klinikleri Journal of Medical Sciences , vol.32, no.4, pp.1084-1089, 2012 (SCI-Expanded) Sustainable Development

124. Lymphoproliferative disorders in multiple primary cancers

Demirci U., ÖZDEMİR N., Benekli M., Babacan N. A., Cetin B., Baykara M., et al.

Asian Pacific Journal of Cancer Prevention , vol.13, no.1, pp.383-386, 2012 (SCI-Expanded)

125. Hyperkalemia in a patient with advanced hepatocellular carcinoma probably due to sorafenib: Case report I{cyrillic, ukrainian}lerlemiş hepatoselüler karsinomlu hastada muhtemelen Sorafenibe baǧ olan hiperkalemi

Üyetürk Ü., Budakoǧlu B., Helvaci K., Uysal Sönmez Ö., Türker I., Yalçintaş Arslan Ü., et al.

Turkiye Klinikleri Journal of Medical Sciences , vol.32, no.2, pp.585-587, 2012 (SCI-Expanded) Sustainable Development

126. Small cell carcinoma of the urinary bladder with hypercalcemia

Şendur M. A. N., AKSOY S., Arik Z., Yaman Ş., Özdemir N. Y., Uncu D., et al.

Medical Oncology , vol.29, no.2, pp.827-828, 2012 (SCI-Expanded)

127. Prognostic factors and treatment outcomes in 93 patients with uterine sarcoma from 4 centers in Turkey

Durnali A., Tokluoǧlu S., Özdemir N., İNANÇ M., Alkiş N., ZENGİN N., et al.

Asian Pacific Journal of Cancer Prevention , vol.13, no.5, pp.1935-1941, 2012 (SCI-Expanded)

128. Abo and rh blood groups and risk of colorectal adenocarcinoma

Ürün Y., Özdemir N. Y., Utkan G., Akbulut H., Savaş B., Öksüzoǧlu B., et al.

Asian Pacific Journal of Cancer Prevention , vol.13, no.12, pp.6097-6100, 2012 (SCI-Expanded)

129. Taxanes in the adjuvant treatment of node-negative breast cancer patients

Ozdemir N., AKSOY S., ZENGİN N., Altundag K.

Journal of B.U.ON. , vol.17, no.1, pp.27-32, 2012 (SCI-Expanded) Sustainable Development

130. Imatinib-induced anasarca without heart failure: Capillary leakage?

Nahit Sendur M., Aksoy S., Civelek B., ZENGİN N., AKSOY S.

Journal of B.U.ON. , vol.17, no.1, pp.188-189, 2012 (SCI-Expanded)

131. Is there an association between blood group and survival in pancreatic cancer?

Kos F. T., Civelek B., ŞEKER M., ARIK Z., AKSOY S., Uncu D., et al.

Asian Pacific Journal of Cancer Prevention , vol.13, no.12, pp.6151-6153, 2012 (SCI-Expanded)

132. Efficacy of angiotensin-receptor blockers on demographic and clinico-pathological characteristics of breast cancer

Şendur M. A., AKSOY S., Yaman S., Ozdemir N. Y., ZENGİN N., Altundag K.

Breast , vol.21, no.3, pp.419-420, 2012 (SCI-Expanded) Sustainable Development

133. Safety and efficacy of FOLFIRI-bevacizumab for metastatic colorectal carcinoma as second line treatment

Odabas H., Ozdemir N., Isik M., Abali H., Oksuzoglu B., Kos T., et al.

Journal of B.U.ON. , vol.16, no.3, pp.460-463, 2011 (SCI-Expanded) Sustainable Development

134. Adjuvant therapy for gallbladder and bile duct cancers: Retrospective comparative study

Tugba Kos F., AKSOY S., Odabas H., Ozdemir N., Oksuzoglu B., Uncu D., et al.

Journal of B.U.ON. , vol.16, no.3, pp.464-468, 2011 (SCI-Expanded) Sustainable Development

135. Gemcitabine and cisplatin in patients with carcinoma of unknown primary site

Isik M., Seker M. M., Odabas H., Kos F. T., Uncu D., ZENGİN N.

Medical Oncology , vol.28, no.2, pp.591-596, 2011 (SCI-Expanded) Sustainable Development

136. Comparison of cisplatin-5-fluorouracil-folinic acid versus modified docetaxel-cisplatin-5-fluorouracil regimens in the first-line treatment of metastatic gastric cancer

Kos F. T., Uncu D., Özdemir N., Budakoglu B., Odabaş H., Abali H., et al.

Chemotherapy , vol.57, no.3, pp.230-235, 2011 (SCI-Expanded) Sustainable Development

137. Long term survival in a metastatic alveolar soft part sarcoma at the time of diagnosis: A case with 17 years of follow-up

Kos F. T., Uncu D., Oksuzoglu B., AKSOY S., Ozdemir N., Odabas H., et al.

Journal of B.U.ON. , vol.16, no.2, pp.376-377, 2011 (SCI-Expanded)

138. Gastric adenocarcinoma under the age of 40; more metastatic, less differentiated

Isik M., Caner S., Metin Seker M., Civelek B., Odabas H., Ozdemir N., et al.

Journal of B.U.ON. , vol.16, no.2, pp.253-256, 2011 (SCI-Expanded) Sustainable Development

139. First-line therapy for metastatic colorectal carcinoma: Modified FOLFOX4 or FOLFIRI-bevacizumab

Odabas H., Ozdemir N., Abali H., Oksuzoglu B., Isik M., Uncu D., et al.

Journal of B.U.ON. , vol.16, no.2, pp.247-252, 2011 (SCI-Expanded) Sustainable Development

140. Successful management of bevacizumab-associated surgical bleeding with an ankaferd blood stopper

Ozdemir N., AKSOY S., Eren T., Uncu D., Bülent Akinci M., Alaguney M. E., et al.

Asian Pacific Journal of Cancer Prevention , vol.12, no.4, pp.1103-1104, 2011 (SCI-Expanded)

141. Bevacizumab: A new potential therapeutic option in sinusoidal obstruction syndrome

Şendur M. A. N., AKSOY S., Arik Z., Yaman Ş., Özdemir N. Y., Uncu D., et al.

Asian Pacific Journal of Cancer Prevention , vol.12, no.8, pp.2147-2148, 2011 (SCI-Expanded)

142. Rapid pleurodesis in malignant pleural effusion: A clinical study and literature review Malign plevra efüzyonunda hızlı plörodez: Klinik çalışma ve literatür derlemesi

Yazkan R., Yildirim E., Dural K., ZENGİN N., Sakinci Ü.

Turkish Journal of Thoracic and Cardiovascular Surgery , vol.19, no.3, pp.410-416, 2011 (SCI-Expanded)

143. Adjuvant modified FOLFOX-4 in patients with stage III rectum adenocarcinoma.

Cihan Ş., Uncu D., Babacan N. A., Özdemir N., Odabaş H., AKSOY S., et al.

Asian Pacific journal of cancer prevention : APJCP , vol.12, no.4, pp.967-970, 2011 (SCI-Expanded) Sustainable Development

144. Breast cancer subtypes and outcomes of central nervous system metastases

Arslan U. Y., Oksuzoglu B., AKSOY S., Harputluoglu H., Turker I., Ozisik Y., et al.

Breast , vol.20, no.6, pp.562-567, 2011 (SCI-Expanded) Sustainable Development

145. The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma

Özdemir N. Y., AbalI H., Öksüzoǧlu B., Budakoglu B., Uncu D., Güler T., et al.

Medical Oncology , vol.27, no.3, pp.680-684, 2010 (SCI-Expanded) Sustainable Development

146. Fifty-one Kaposi sarcoma patients

Dogan M., Dogan L., Ozdemir F., Yildirim Ozdemir N., Senol Coskun H., Yalcintas Arslan U., et al.

Clinical and Translational Oncology , vol.12, no.9, pp.629-633, 2010 (SCI-Expanded) Sustainable Development

147. Adjuvant bi-weekly combination of cisplatin, infusional 5-fluorouracil and folinic acid followed by concomitant chemoradiotherapy with infusional fluorouracil for high risk operated gastric and gastroesophageal junction adenocarcinoma

Uncu D., Ozdemir N. Y., AKSOY S., Abali H., Oksuzoglu B. C., Budakoglu B., et al.

Asian Pacific Journal of Cancer Prevention , vol.11, no.6, pp.1493-1497, 2010 (SCI-Expanded) Sustainable Development

148. It appears to be safe to start chemotherapy on the day of implantation through subcutaneous venous port catheters in inpatient setting

Özdemir N. Y., AbalI H., Öksüzoǧlu B., Budakoǧlu B., Akmangit I., ZENGİN N.

Supportive Care in Cancer , vol.17, no.4, pp.399-403, 2009 (SCI-Expanded)

149. Capecitabine and cisplatin combination is an active and well-tolerated doublet in the treatment of metastatic breast carcinoma patients pretreated with anthracycline and taxanes

Öksüzoglu B., Abali H., HAYRAN K. M., Yildirim N., Budakoglu B., ZENGİN N.

Chemotherapy , vol.54, no.5, pp.352-356, 2008 (SCI-Expanded) Sustainable Development

150. Prognostic factors and clinicopathological characteristics of carcinoma of ampulla vateri

Pamukcuoglu M., Oksuzoglu B., Abali H., Akoglu M., Atalay F., Budakoglu B., et al.

International Surgery , vol.93, no.4, pp.214-219, 2008 (SCI-Expanded)

151. Comparison of ICE (Ifosfamide-Carboplatin-Etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma

Abali H., ÜRÜN Y., Öksüzoǧlu B., Budakoǧlu B., Yüldürüm N., Güler T., et al.

Cancer Investigation , vol.26, no.4, pp.401-406, 2008 (SCI-Expanded)

152. Intraabdominal desmoplastic small round cell tumor mimicking renal cell cancer: A case report and review of the literature Böbrek hücreli kanseri taklit eden abdominal kaynakli desmoplastik kücük yuvarlak hücreli tümör: Bir olgu sunumu ve yayinlarin gözden geçirilmesi

Tuncel A., Aslan Y., Yildirim Ü., ZENGİN N., Atan A.

Turk Uroloji Dergisi , vol.34, no.1, pp.128-132, 2008 (SCI-Expanded) Sustainable Development

153. Whole body 18F-FDG PET/CT imaging in the detection of primary tumours in patients with a metastatic carcinoma of unknown origin

KAYA A., UĞUR Ş., ÜNLÜ M., AKDEMİR Ü. Ö., Ozdemir N. Y., ZENGİN N., et al.

Asian Pacific Journal of Cancer Prevention , vol.9, no.4, pp.683-686, 2008 (SCI-Expanded) Sustainable Development

154. The effect of regimes of harvesting autologous peripheric stem cell on the number of CD34(+) cell: Experience at a single center Otolog periferik kök hücre toplama rejimlerinin CD34(+) hücre sayisi üzerine etkisi: Tek merkez deneyimi

Şahin Balçik Ö., Daǧdaş S., Keser Güler S., Özet G., Oymak A., Çelik Z., et al.

Turkiye Klinikleri Journal of Medical Sciences , vol.28, no.5, pp.640-647, 2008 (SCI-Expanded)

155. Cerebrovascular accident during cisplatin-based combination chemotherapy of testicular germ cell tumor: An unusual case report

Azak A., Öksüzoǧlu B., Deren T., Öneç B. M., ZENGİN N.

Anti-Cancer Drugs , vol.19, no.1, pp.97-98, 2008 (SCI-Expanded)

156. Good tolerance of high dose cytosine arabinoside and methotrexate after severe myelosuppression secondary to intrathecal administration of the same agents

Yildirim N., Abali H., Güler T., Öksüzoǧlu B., Pamukçu M., ZENGİN N.

Turkish Journal of Hematology , vol.24, no.3, pp.140-141, 2007 (SCI-Expanded)

157. Multiple myeloma in a patient with neurofibromatosis [1]

ZENGİN N., Gönül M., Gül Ü., Öksüzoǧlu B., Kiliç A., Çakmak S. K., et al.

American Journal of Hematology , vol.82, no.8, pp.772, 2007 (SCI-Expanded)

158. Blood flow indices by doppler ultrasonography vary with neoadjuvant chemotherapy but are not related to plasma VEGF levels in locally advanced breast cancer

Öksüzoǧlu B., Vural M., Abali H., Yilmaz M., Yildirim N., ZENGİN N.

Oncology , vol.71, no.3-4, pp.185-189, 2007 (SCI-Expanded) Sustainable Development

159. Tamoxifen induced-thrombocytopenia: It does occur

Nasıroğlu N., Pamukçuoğlu M., Abalı H., Öksüzoğlu B., ÜNER A., ZENGİN N.

Medical Oncology , vol.24, no.4, pp.453-454, 2007 (SCI-Expanded) Sustainable Development

160. An extraordinary case in whom gastrointestinal stromal tumor and low-grade malignant lymphoma are seen together in the stomach

Pamukçuoğlu M., Budakoğlu B., Han Ö., Tad M., Öksüzoğlu B., Abalı H., et al.

Medical Oncology , vol.24, no.3, pp.351-353, 2007 (SCI-Expanded)

161. Cavernous sinus syndrome caused by metastatic colon carcinoma

Öneç B., Öksüzoǧlu B., Hatipoǧlu H. G., Öneç K., Azak A., ZENGİN N.

Clinical Colorectal Cancer , vol.6, no.8, pp.593-596, 2007 (SCI-Expanded) Sustainable Development

162. Sinonasal NK/T-cell lymphoma mimicking Wegener's granulomatosis: A case report Wegener granülomatozisi taklit eden sinonazal böige tutulumlu NK/T-hücreli lenfoma: Olgu sunumu

Pamukçuoǧlu M., Nasiroǧlu N., Yildirim N., Özçelik Ö., Öksüzoǧlu B., Abali H., et al.

Tuberkuloz ve Toraks , vol.54, no.3, pp.277-280, 2006 (SCI-Expanded)

163. Prognostic factors of non-Hodgkin lymphoma Non-Hodgkin lenfomada prognostik parametreler

Uncu D., Abali H., Özdemir N., Budakoǧlu B., Güler T., Öksüzoǧlu B. Ç., et al.

UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi , vol.16, no.1, pp.27-31, 2006 (SCI-Expanded)

164. Performance status scales may not correctly predict status of cancer patients with paraplegia

Budakoglu B., Abali H., Çakmaköksüzoglu B., AKSOY S., ZENGİN N.

Cancer Investigation , vol.24, no.2, pp.221-222, 2006 (SCI-Expanded) Sustainable Development

165. Disclosure of cancer diagnosis to patients and their relatives in Turkey: Views of accompanying persons and influential factors in reaching those views

Öksüzoǧlu B., Abali H., Bakar M., Yildirim N., ZENGİN N.

Tumori , vol.92, no.1, pp.62-66, 2006 (SCI-Expanded) Sustainable Development

166. Cisplatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: A randomised phase III trial of Turkish Oncology Group

Icli F., Akbulut H., Uner A., Yalcin B., Baltali E., Altinbas M., et al.

British Journal of Cancer , vol.92, no.4, pp.639-644, 2005 (SCI-Expanded)

167. Rapid pleurodesis in symptomatic malignant pleural effusion

Yildirim E., Dural K., Yazkan R., ZENGİN N., Yildirim D., Gunal N., et al.

European Journal of Cardio-thoracic Surgery , vol.27, no.1, pp.19-22, 2005 (SCI-Expanded)

168. Case report: Cavernous sinus metastasis of the parotid carcinoma: A very unusual case

Yıldırım N., Üksüzoǧlu B., Vural M., Han Ö., ZENGİN N.

Journal of Neuro-Oncology , vol.73, no.2, pp.181-183, 2005 (SCI-Expanded)

169. Primary duodenal diffuse large cell non-hodgkin lymphoma with involvement of ampulla of Vater: Report of 3 cases

Yildirim N., Öksüzoǧlu B., Budakoǧlu B., Vural M., Abal H., Uncu D., et al.

Hematology , vol.10, no.5, pp.371-374, 2005 (SCI-Expanded)

170. Good tolerance of weekly irinotecan in a patient with metastatic colorectal cancer on chronic hemodialysis

Budakoglu B., Abali H., Uncu D., Yildirim N., Öksüzoglu B., ZENGİN N.

Journal of Chemotherapy , vol.17, no.4, pp.452-453, 2005 (SCI-Expanded) Sustainable Development

171. Prospective study of combined modality treatment or radiotherapy alone in the management of early-stage adult Hodgkin's disease

YILDIZ F., ZENGİN N., Engin H., Güllü I., BARIŞTA İ., Çaglar M., et al.

International Journal of Radiation Oncology Biology Physics , vol.60, no.3, pp.839-846, 2004 (SCI-Expanded)

172. Analysis of menstrual, reproductive, and life-style factors for breast cancer risk in turkish women: A case-control study

Oran B., ÇELİK İ., ERMAN M., Baltali E., ZENGİN N., DEMİRKAZIK F., et al.

Medical Oncology , vol.21, no.1, pp.31-39, 2004 (SCI-Expanded) Sustainable Development

173. Use of hydroxyurea and α-interferon in chronic myeloid leukemia during pregnancy: A case report

Baykal C., ZENGİN N., COŞKUN F. M., Güler N., Ayhan A.

European Journal of Gynaecological Oncology , vol.21, no.1, pp.89-90, 2000 (SCI-Expanded)

174. Treatment of advanced soft tissue sarcomas with ifosfamide and doxorubicin combination chemotherapy

Barişta I., Tekuzman G., Yalçin Ş., Güllü I., Güler N., Özişik Y., et al.

Journal of Surgical Oncology , vol.73, no.1, pp.12-16, 2000 (SCI-Expanded)

175. Paclitaxel in the salvage treatment of metastatic breast carcinoma

Guler N., Baltali E., Altundag K., ZENGİN N., Tekuzman G., Ozisik Y., et al.

Journal of B.U.ON. , vol.4, no.3, pp.275-281, 1999 (SCI-Expanded)

176. The significance of the bone marrow biopsy pattern in chronic lymphocytic leukemia: A prognostic dilemma

ZENGİN N., Kars A., Sungur A., Zengin N. I., HAYRAN K. M., Tekuzman G., et al.

American Journal of Hematology , vol.62, no.4, pp.208-211, 1999 (SCI-Expanded)

177. Acute lymphoblastic leukaemia presenting with arthritis in an adult patient

Usalan C., Özarslan E., ZENGİN N., Büyükaýk Y., Güllü Ý. H.

Postgraduate Medical Journal , vol.75, no.885, pp.425-427, 1999 (SCI-Expanded)

178. Primary neuroendocrine tumor of the breast

YALÇIN Ş., ZENGİN N., Tekuzman G., Küçükali T.

Medical Oncology , vol.14, no.2, pp.121-123, 1997 (SCI-Expanded)

179. Maintenance therapy with alpha-interferon following first-line VAD in multiple myeloma

Kars A., Çelik I., Kansu E., Tekuzman G., Özişik Y., Güler N., et al.

European Journal of Haematology , vol.59, no.2, pp.100-104, 1997 (SCI-Expanded)

180. High-dose ifosfamide by infusion with Mesna in advanced refractory sarcomas

Güllü I., YALÇIN Ş., Tekuzman G., BARIŞTA İ., Alkiş N., ÇELİK İ., et al.

Cancer Investigation , vol.14, no.3, pp.239-242, 1996 (SCI-Expanded)

Articles Published in Other Journals 13

11. Primary extranodal lymphoma: The comparison of clinical characteristics with nodal lymphoma Primer ekstranodal lenfomalar: Klinik özelliklerinin nodal lenfomalarla karşilaştirilmasi

Uncu D., Özdemir N., Karakan Ş., Öksüzoǧlu B. Ç., ZENGİN N.

THOD - Turk Hematoloji-Onkoloji Dergisi , vol.15, no.2, pp.63-67, 2005 (Scopus)

12. Retrospective Evaluation of Adults with Soft Tissue Ewing Sarcoma and Primitive Neuroectodermal Tumors Yumuşak Doku Ewing Sarkomu ve Primitif Nöroektodermal Tümörlü Erişkin Olgularin Retrospektif Deǧerlendirilmesi

Karakan Š., Öksüzoǧlu B., Uncu D., Yildirim N., Budakoǧlu B., Küçükazman M., et al.

THOD - Turk Hematoloji-Onkoloji Dergisi , vol.14, no.1, pp.14-19, 2004 (Scopus)

13. Docetaxel (Taxotere) in the salvage treatment of anthracycline resistant metastatic breast cancer

Guler N., Baltali E., Altundag K., ZENGİN N., Ozisik Y., Tekuzman G., et al.

Turkish Journal of Cancer , vol.29, no.3, pp.119-129, 1999 (Scopus) Sustainable Development

Papers Presented at Peer-Reviewed Scientific Conferences 1

1. Docetaxel Associated Acute Myositis in a Patient with Stomach Cancer.

Eruyar E., Zengin N.

. 10 th International Hippocrates Congress on Medical and Health Sciences, Ankara, Turkey, 16 - 17 December 2022, pp.163-166, (Full Text)

Metrics

Publication

194

Publication (WoS)

163

Publication (Scopus)

191

Citation (WoS)

1114

H-Index (WoS)

Citation (Scopus)

1327

H-Index (Scopus)

Thesis Advisory

Open Access

UN Sustainable Development Goals

Publications & Works